

Cell-free DNA Testing Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017–2023

<https://marketpublishers.com/r/C82D8623C3AEN.html>

Date: November 2017

Pages: 96

Price: US\$ 2,750.00 (Single User License)

ID: C82D8623C3AEN

Abstracts

Cell-free DNA Testing Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017–2023

Overview: Cell-free DNA (cfDNA) are non-encapsulated fragments of DNA molecule present in blood and urine that has huge screening and diagnostic applications. CfDNA is used for fetal DNA screening tests to detect chromosomal abnormalities, as a biomarker for specific mutations detection in cancer patients, as a biomarker to detect post transplantation rejection, and other applications. According to the Center of Disease Control and Prevention, around 6,000 babies are born with Down syndrome every year that is nearly 1 in every 700 babies and the disease incidence is increased by about 30% between 1979 and 2003. Further, according to the study by World Health Organization, approximately 14 million new cancer cases were diagnosed and is expected to grow by about 70% over the next 2 decades.

The cfDNA testing market is booming due to advanced maternal age, increasing number of chronic diseases, change in lifestyle that leads to lifestyle diseases like cancer, and unhealthy food habits. The rising disease incidence along with the increasing medical spending and healthcare expenditure provide opportunities for molecular diagnostics company to come up with more number of innovative tests in the market. However, there is a huge market space for molecular diagnostic companies to come up with novel tests directing on transplantation rejection cases like liver, lung, etc, in the near future.

Market Analysis: The “Global Cell-free DNA Testing Market” is estimated to witness a CAGR of 26.5% during the forecast period 2017–2023. The market is analyzed based

on three segments, namely test types, application, and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the cfDNA testing market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions.

Test Types Analysis: The global cfDNA testing market by test type is segmented into cell-free fetal DNA tests (also called NIPT), circulating tumor DNA tests, and donor-derived cell-free DNA tests. Cell-free fetal DNA tests is the largest segment, as women are more career-oriented, and the trend is seen in western countries to start family at a late age. These lead to an increase in the average maternal age. Donor-derived cfDNA tests are the fastest growing segment. The rising number of organ donors, increasing transplantation procedures, increasing healthcare awareness have made them the fastest growing segment of the market. The market is also witnessing various acquisitions, agreements, and new product launches and collaborations among the top players, which is defining the future of the global cfDNA testing market.

Application Analysis: The global cfDNA testing market by application is segmented into Gynecology, Oncology, and Transplantation. Gynecology occupies the largest market share and transplantation is expected to be the fastest growing segment during the forecasted period.

Key Players: Natera, Inc., Beijing Genomics Institute, F. Hoffmann-La Roche (Roche), Laboratory Corporation of America Holdings, Illumina, Inc., Guardant Health, Trovagene, Inc., Biocept, Inc., and other predominate & niche players.

Competitive Analysis: Currently, the cfDNA tests dominate the global cfDNA testing market. A lot of new players are focusing on this market to provide innovative tests with high accuracy and less turnaround time. Many major players in the market are launching new products to maintain their leadership in the market. Apart from this, the big players are acquiring small companies in the market to enhance their product portfolio and maintain their market leadership. For instance, in September 2016, LabCorp acquired Sequenom to strengthen its non-invasive prenatal testing product portfolio.

Benefits: The report provides complete details about the usage and adoption rate of cfDNA tests in various applications and regions. With that, the key stakeholders can know about the major trends, drivers, investments, vertical player's initiatives,

government initiatives toward the test adoption in the upcoming years along with the details of commercial tests available in the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

Contents

1 INDUSTRY OUTLOOK

- 1.1 Industry overview
- 1.2 Total addressable market
- 1.3 Industry Trends

2 REPORT OUTLINE

- 2.1 Report Scope
- 2.2 Report Summary
- 2.3 Research Methodology
- 2.4 Report Assumptions

3 MARKET SNAPSHOT

- 3.1 Market Definition – Infoholic Research
- 3.2 Importance of Cell-Free DNA testing
- 3.3 Complications of Cell-Free DNA testing
- 3.4 Segmented Addressable Market (SAM)
- 3.5 Industry Trends
- 3.6 Related Markets
 - 3.6.1 Liquid biopsy market
 - 3.6.2 Transplantation Diagnostics Market

4 MARKET OUTLOOK

- 4.1 Overview
- 4.2 Regulatory framework
- 4.3 Funding scenario
- 4.4 Market segmentation
- 4.5 PEST Analysis
- 4.6 Porter 5(Five) Forces

5 MARKET CHARACTERISTICS

- 5.1 DRO – Global Cell-free DNA testing Market Dynamics
 - 5.1.1 Drivers

5.1.1.1 Rising incidence of babies with chromosomal disorders due to increasing number of late pregnancies

5.1.1.2 Rising number of cancers

5.1.1.3 Growing demand through non-invasive procedures for early disease diagnosis

5.1.2 Opportunities

5.1.2.1 Increase healthcare spending and growing healthcare awareness in emerging countries

5.1.2.2 Increase in mergers & acquisitions

5.1.3 Restraints

5.1.3.1 High test cost with less reimbursement facilities

5.1.3.2 Ethical issues

5.1.3.3 Lack of skilled professionals for performing advanced diagnostic testing

6 TEST TYPES: MARKET SIZE AND ANALYSIS

6.1 Overview

6.2 Non-invasive prenatal testing (NIPT)

6.3 Circulating tumour DNA tests

6.4 Donor-derived cell free DNA tests

7 APPLICATION: MARKET SIZE AND ANALYSIS

7.1 Overview

7.2 Prenatal testing

7.3 Cancer

7.4 Transplantation diagnostics

8 REGIONS: MARKET SIZE AND ANALYSIS

8.1 Overview

8.2 North America

8.2.1 Overview

8.2.2 United states

8.2.3 Canada

8.3 Europe

8.3.1 Overview

8.3.2 United Kingdom

8.3.3 Germany

- 8.3.4 France
- 8.3.5 Spain
- 8.4 APAC
 - 8.4.1 Overview
 - 8.4.2 India
 - 8.4.3 China
- 8.5 Rest of the World
 - 8.5.1 Overview
 - 8.5.2 Brazil
 - 8.5.3 Middle East

9 COMPETITIVE LANDSCAPE

- 9.1 Overview

10 VENDOR PROFILES

- 10.1 Natera, Inc.
 - 10.1.1 Overview
 - 10.1.2 Natera Inc.:Product offerings
 - 10.1.3 NATERA, INC.: Recent Developments
 - 10.1.4 Geographic Presence
 - 10.1.5 Business Focus
 - 10.1.6 SWOT Analysis
 - 10.1.7 Business Strategy
- 10.2 Laboratory Corporation of America Holdings (LABCORP)
 - 10.2.1 Overview
 - 10.2.2 Laboratory Corporaton Of America Holdings: Product Offerings
 - 10.2.3 Laboratory Corporation Of America Holdings: Recent Developments
 - 10.2.4 Business Unit
 - 10.2.5 Geographic Presence
 - 10.2.6 Business Focus
 - 10.2.7 SWOT Analysis
 - 10.2.8 Business Strategy
- 10.3 Illumina, Inc.,
 - 10.3.1 Overview
 - 10.3.2 Illumina, INC: Product offerings
 - 10.3.3 Illumina, INC: Recent Developments
 - 10.3.4 Geographic Presence

- 10.3.5 Business Focus
- 10.3.6 SWOT Analysis
- 10.3.7 Business Strategy
- 10.4 BEIJING GENOMICS INSTITUTE
 - 10.4.1 Overview
 - 10.4.2 Beijing Genomics Institute: Product offerings
 - 10.4.3 Beijing Genomics Institute: Recent Developments
 - 10.4.4 Business Focus
 - 10.4.5 SWOT Analysis
 - 10.4.6 Business Strategy
- 10.5 F.Hoffmann-La Roche Ltd
 - 10.5.1 Overview
 - 10.5.2 F. Hoffmann-la Roche: Product Offerings
 - 10.5.3 F. Hoffmann-la roche.: Recent Developments
 - 10.5.4 Business Unit
 - 10.5.5 Geographic Presence
 - 10.5.6 Business Focus
 - 10.5.7 SWOT Analysis
 - 10.5.8 Business Strategy
- Companies to Watch For
- 10.6 CareDx, Inc
 - 10.6.1 Overview
 - 10.6.2 caredx: Recent Developments
- 10.7 LifeCodexx AG
 - 10.7.1 Overview
 - 10.7.2 LifeCodexx AG: Recent Developments
- 10.8 Biocept, Inc.
 - 10.8.1 Overview
 - 10.8.2 Biocept, Inc.: Recent Developments
- 10.9 Quest Diagnostics
 - 10.9.1 Overview
 - 10.9.2 Quest Diagnostics: Recent Developments
- 10.10 Guardant Health
 - 10.10.1 Overview
 - 10.10.2 Guardant Health: Recent Developments
- 10.11 Inivata Limited
 - 10.11.1 Overview
 - 10.11.2 Inivata Limited: Recent Developments
- 10.12 Personal Genome Diagnostics

- 10.12.1 Overview
- 10.12.2 Personal Genome Diagnostics: Recent Developments
- 10.13 Trovagene
 - 10.13.1 Overview
 - 10.13.2 Trovagene, Inc.: Recent Developments
- Annexure
- Abbreviations

Tables

- Table 1 FUNDING SCENARIO
- Table 2 GLOBAL CELL-FREE DNA TESTING MARKET BY TEST TYPES, 2016–2023 (\$MILLION)
- Table 3 GLOBAL CELL-FREE DNA TESTING MARKET BY APPLICATION, 2016–2023 (\$MILLION)
- Table 4 GLOBAL CELL-FREE DNA TESTING MARKET REVENUE BY REGIONS, 2016–2023 (\$MILLION)
- Table 5 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET BY VENDOR RANKING, 2016
- Table 6 OTHER PROMINENT VENDORS OF CELL-FREE DNA TESTING MARKET
- Table 7 CAREDX, INC.: SNAPSHOT
- Table 8 LIFECODEXX AG.: SNAPSHOT
- Table 9 BIOCEPT, INC.: SNAPSHOT
- Table 10 QUEST DIAGNOSTICS: SNAPSHOT
- Table 11 GUARDANT HEALTH INC.: SNAPSHOT
- Table 12 INIVATA LIMITED: SNAPSHOT
- Table 13 PERSONAL GENOME DIAGNOSTICS: SNAPSHOT
- Table 14 TROVAGENE, INC.: SNAPSHOT

Charts

- Chart 1 RESEARCH METHODOLOGY OF GLOBAL CELL-FREE DNA TESTING MARKET
- Chart 2 WORLDWIDE CELL-FREE DNA TESTING MARKET REVENUE, 2016–2023 (\$MILLION)
- Chart 3 PEST ANALYSIS OF GLOBAL CELL-FREE DNA TESTING MARKET
- Chart 4 PORTER 5 FORCES ON GLOBAL CELL-FREE DNA TESTING MARKET
- Chart 5 DRO – IMPACT ANALYSIS OF GLOBAL CELL-FREE DNA TESTING MARKET
- Chart 6 KEY STAKEHOLDERS
- Chart 7 GLOBAL CELL-FREE DNA TESTING MARKET BY TEST TYPE SEGMENTATION, 2016 (%)

Chart 8 GLOBAL CELL-FREE DNA TESTING MARKET BY TEST TYPE
SEGMENTATION, 2023 (%)

Chart 9 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET REVENUE
FORECAST,

2016–2023 (\$MILLION)

Chart 10 GLOBAL CIRCULATING TUMOUR DNA MARKET REVENUE FORECAST,
2016–2023 (\$MILLION)

Chart 11 GLOBAL DONOR-DERIVED CELL-FREE DNA TESTING MARKET
REVENUE FORECAST, 2016–2023 (\$MILLION)

Chart 12 GLOBAL CELL-FREE DNA TESTING MARKET BY APPLICATION
SEGMENTATION, 2016 (%)

Chart 13 GLOBAL CELL-FREE DNA TESTING MARKET BY APPLICATION
SEGMENTATION, 2023 (%)

Chart 14 GLOBAL CELL-FREE DNA TESTING MARKET BY GEOGRAPHICAL
SEGMENTATION, 2016 (%)

Chart 15 CELL-FREE DNA TESTING MARKET REVENUE IN NORTH AMERICA,
2016–2023 (\$MILLION)

Chart 16 CELL-FREE DNA TESTING MARKET REVENUE IN EUROPE, 2016–2023
(\$MILLION)

Chart 17 CELL-FREE DNA TESTING MARKET REVENUE IN ASIA-PACIFIC,
2016–2023 (\$MILLION)

Chart 18 CELL-FREE DNA TESTING MARKET REVENUE IN REST OF THE WORLD,
2016–2023 (\$MILLION)

Chart 19 NATERA: OVERVIEW SNAPSHOT

Chart 20 NATERA: GEOGRAPHIC PRESENCE

Chart 21 NATERA: SWOT ANALYSIS

Chart 22 LABORATORY CORPORATION OF AMERICA HOLDINGS: OVERVIEW
SNAPSHOT

Chart 23 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS
UNITS

Chart 24 LABORATORY CORPORATION OF AMERICA HOLDINGS:
GEOGRAPHICAL PRESENCE

Chart 25 LABORATORY CORPORATION OF AMERICA HOLDINGS: SWOT
ANALYSIS

Chart 26 ILLUMINA, INC: OVERVIEW SNAPSHOT

Chart 27 ILLUMINA, INC: GEOGRAPHIC PRESENCE

Chart 28 ILLUMINA, INC: SWOT ANALYSIS

- Chart 29 BEIJING GENOMICS INSTITUTE: SWOT ANALYSIS
- Chart 30 F. HOFFMANN-LA ROCHE: OVERVIEW SNAPSHOT
- Chart 31 F. HOFFMANN-LA ROCHE: BUSINESS UNITS
- Chart 32 F. HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE
- Chart 33 F. HOFFMANN-LA ROCHE: SWOT ANALYSIS

I would like to order

Product name: Cell-free DNA Testing Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017–2023

Product link: <https://marketpublishers.com/r/C82D8623C3AEN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C82D8623C3AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

